An observational study in Diabetes and Coronary Artery Calcification, sponsored by VeraLight, Inc.. Completed at 1 site in United States. Open to participants aged 45 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-10-12.
Sponsored by VeraLight, Inc. · Observational
This study examines the relationship between the SCOUT DM device and coronary artery calcification as determined by rapid computed tomography in patients at risk for coronary heart disease.
This is a cross-sectional, single site, cohort screening trial. The correlation between the measured skin fluorescence and the CACS will be determined using a design that includes stratification by gender, subject age and subject CAC score. This design requires a single patient visit to the clinical site and a single measurement on the SCOUT device.
317 studies on the registry are indexed under Arteriosclerosis; 33 are open to participants now.
This study's planned enrollment of 240 is below the median of 330 across 99 observational studies indexed under Arteriosclerosis.
Browse Arteriosclerosis studies →VeraLight, Inc. is the lead sponsor of 14 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Subjects are sorted into the follwoing categories for age (years): men:45-54,55-64,65+, women: 50-59, 60-69, 70+. In addition, subjects will be sorted into the follwoing categories for CACS:0-10, 11-100, 101-400, 401-1000, >1000 and absence/presence of diagnosed diabetes (type 1 or type 2)
Exclusion Criteria:
Male ages 45-54, without diabetes, CAC score from 0 to \>1000
Male ages 55-64, without diabetes, CAC score from 0 to \>1000
Male ages 65+, without diabetes, CAC score from 0 to \>1000
Male ages 45-54, with diabetes and CAC score from 0 to \>1000
Male ages 55-64, with diabetes, CAC score from 0 to \>1000
Male ages 65+, with diabetes, CAC score from 0 to \>1000
Female ages 50-59, without diabetes, CAC score from 0 to \>1000
Females ages 60-69, without diabetes and CAC score from 0 to \>1000
Females ages 70 +, without diabetes, CAC score from 0 to \>1000
Female ages 50- 59, with diabetes, CAC score from 0 to \>1000
Female ages 60-69, with diabetes, CAC score from 0 to \>1000
Female age 70+, with diabetes, CAC score from 0 to \>1000
This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
VeraLight, Inc.